Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease

Neurology

Volumn 50, Issue 5, 1998, Pages 1366-1373

  Marshall, Frederick J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N (7 HYDROXY 2,2,4,6 TETRAMETHYL 1 INDANYL) 4 (3 METHOXYPHENYL) 1 PIPERAZINEACETAMIDE; PLACEBO; SCAVENGER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRAIN SYNAPTOSOME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLIOSIS; HUMAN; HUNTINGTON CHOREA; INVOLUNTARY MOVEMENT; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NERVE DEGENERATION; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE;

EID: 0344625374     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.5.1366     Document Type: Article

References (43)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-98.3.
2. Greenamyre JT, Shoulson I. Huntington's disease. In: Calne DB, ed. Neurodegenerative diseases. Philadelphia: WB Saunders, 1994:685-704.
3. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-375.
4. Coyle JT, Schwarcz R. Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea Nature 1976; 263:244-246.
5. McGeer EG, McGeer PL. Duplication of biochemical changes of Huntington's chorea by interstriatal injections of glutamic and kainic acids. Nature 1976;263:517-519.
6. Schwarcz R, Whetsell WO, Mangano RN. Quinolinic acid: an endogenous metabolite that produces axon sparing lesions in rat brain. Science 1982;219:316-318.
7. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986;321: 168-171.
8. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 1991;11:1649-1659.
9. Beal MF, Brouillet E, Jenkins BG, et al. Neurochemical and histological characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitroproprionic acid J Neurosci 1993;13:4181-4192.
10. Beal MF, Brouillet E, Jenkins BG, Henshaw R, Rosen B, Hyman BT. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate J Neurochem 1993;61:1147-1150.
11. Greene JG, Porter MP, Eller RB, Greenamyre JT. Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoxic" lesion in rat striatum. J Neurochem 1993;61:1151-1154.
12. Beal MF, Henshaw DR, Jenkins BG, Rosen BR, Schulz JB. Coenzyme Q10 and nicotinamide blocks striatal lesions produced by the mitochondrial toxin malonate Ann Neurol 1994; 36:882-888.
13. Schulz JB, Matthews RT, Henshaw DR, Beal MF. Neuroprotective strategies for treatment of lesions produced by mitochondria! toxins: implications for neurodegenerative disease Neuroscience 1996;71:1043-1048.
14. Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1HNMR spectroscopy. Neurology 1993;43: 2689-2695.
15. Koroshetz WJ, Jenkins B, Rosen B, Beal MF. Ubiquinone lowers occipital lactate levels in patients with Huntington's disease. Neurology 1993;43(suppl 14):A334. Abstract.
16. Coyle JT, Puttfarken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993;262:689-700.
17. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease N Engl J Med 1993;328:176-183.
18. Peyser CE, Folstein M, Chase GA, et al. Trial of d-alpha tocopherol in Huntington's disease. Am J Psychiatry 1995; 152:1771-1775.
19. Tottori K, Kikuchi T, Uwahodo Y, Nakai M, Miwa T, Hirose T. Protective effects of OPC-14117 on dopaminergic neuronal degeneration induced by MPTP in ICR mice. Jpn J Pharmacol 1995;67(suppl 1):144p. Abstract.
20. Fisher M, Arpano M. Inhibition of stimulated leukocyte hydrogen peroxide generation by a novel antioxidant OPC-14117. J Neurosci 1992;109:107-110.
21. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Movement Disorders 1996;11:136-142.
22. Conners CK, Barkley RA. Rating scales and checklists for psychopharmacologic trials. Psychopharmacol Bull 1985;21: 809-854.
23. Smith A. Symbol digit modalities test manual. Los Angeles: Western Psychological Services, 1982.
24. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935;18:643-662.
25. Benton AL, Hamsher K de S. Multilingual aphasia examination manual. Iowa City: University of Iowa, 1978.
26. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery. Tucson: Neuropsychology Press, 1985.
27. Brandt J. The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clin Neuropsychol 1991;5:126-142.
28. Wechsler D. Wechsler Adult Intelligence Scale - Revised. San Antonio: The Psychological Corporation, 1981.
29. Cooper JA, Sagar HJ. Incidental and intentional recall in Parkinson's disease: an account based on diminished attentional resources. J Clin Exp Neuropsychol 1993;15:713-731.
30. Petrides M. Nonspatial conditional learning impaired in patients with unilateral frontal but not unilateral temporal lobe excisions. Neuropsychologia 1990;28:137-149.
31. Golden CJ, Purisch AD, Hammeke TA. Luria-Nebraska Neuropsychology Battery: forms I and II. Los Angeles: Western Psychological Association, 1985.
32. Schretlen D, Bobholz JM, Brandt J. Development and psychometric properties of the Brief Test of Attention. Clin Neuropsychol 1998 (in press).
33. Grace J, Malloy P. Frontal Lobe Personality Scale (FLOPS). Providence: Brown University, 1992.
34. Beck AT, Ward CH, Mendelson M, Mack J, Erbaugh JK. An inventory for measuring depression. Arch Gen Psychiatry 1961;14:561-571.
35. Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr 1993;57: 7155-7255.
36. Floyd RA, Watson J, Wonk PK. Sensitive assay of hydroxyl free radical formation utilizing high pressure liquid chromatography with electrochemical detection of phenol and salicylate hydroxylation products. J Biochem Biophys Methods 1984;10:221-235.
37. Levine R, Gurland D, Oliver C, et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990;186:464-478.
38. Giulivi C, Davies KJ. Dityrosine: a marker for oxidatively modified proteins and selective proteolysis. Methods Enzymol 1994;23:363-371.
39. Malencik DA, Zhae ZZ, Anderson SR. Determination of dityrosine, phosphotyrosine, phosphothreonine, and phosphoserine by high-performance liquid chromatography. Anal Biochem 1990;184:353-359.
40. Shoulson I, Kurlan R, Rubin A, et al. Assessment of functional capacity in neurodegenerative movement disorders: Huntington's disease as a prototype. In: Munsat T, ed. Quantification of neurologic deficit. Butterworths: Stoneham, MA, 1989:271-283.
41. Agresti A. Categorical data analysis. New York: Wiley, 1990.
42. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patients. I. Introduction and design. Br J Cancer 1976; 34:585-612.
43. Armitage P. Tests for linear trends in proportions and frequencies. Biometrics 1995;11:375-386.